Acrivon Therapeutics (ACRV) Competitors $1.91 0.00 (0.00%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 05:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. EPRX, SCLX, CRBU, BIOA, BDTX, MDWD, SXTC, CLLS, FTLF, and DERMShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Eupraxia Pharmaceuticals (EPRX), Scilex (SCLX), Caribou Biosciences (CRBU), BioAge Labs (BIOA), Black Diamond Therapeutics (BDTX), MediWound (MDWD), China SXT Pharmaceuticals (SXTC), Cellectis (CLLS), FitLife Brands (FTLF), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors Eupraxia Pharmaceuticals Scilex Caribou Biosciences BioAge Labs Black Diamond Therapeutics MediWound China SXT Pharmaceuticals Cellectis FitLife Brands Journey Medical Acrivon Therapeutics (NASDAQ:ACRV) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Do institutionals & insiders believe in ACRV or EPRX? 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend ACRV or EPRX? Acrivon Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 685.34%. Eupraxia Pharmaceuticals has a consensus target price of $11.00, indicating a potential upside of 82.72%. Given Acrivon Therapeutics' higher possible upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75Eupraxia Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Does the media refer more to ACRV or EPRX? In the previous week, Eupraxia Pharmaceuticals had 9 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 11 mentions for Eupraxia Pharmaceuticals and 2 mentions for Acrivon Therapeutics. Eupraxia Pharmaceuticals' average media sentiment score of 0.74 beat Acrivon Therapeutics' score of 0.52 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ACRV or EPRX more profitable? Acrivon Therapeutics' return on equity of -50.78% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -50.78% -46.08% Eupraxia Pharmaceuticals N/A -626.84%-118.31% Which has preferable valuation and earnings, ACRV or EPRX? Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.85Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.85-7.08 Which has more volatility and risk, ACRV or EPRX? Acrivon Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. SummaryAcrivon Therapeutics beats Eupraxia Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.08M$2.66B$6.12B$10.65BDividend YieldN/A56.92%5.70%4.74%P/E Ratio-0.8523.8685.6626.85Price / SalesN/A745.61622.88135.13Price / CashN/A169.9037.7861.77Price / Book0.345.5913.216.70Net Income-$80.56M$32.78M$3.30B$276.44M7 Day Performance5.52%4.01%3.95%2.48%1 Month Performance6.70%10.63%8.40%8.79%1 Year Performance-72.71%-1.80%88.36%34.41% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics2.55 of 5 stars$1.91flat$15.00+685.3%-72.5%$60.08MN/A-0.8558EPRXEupraxia Pharmaceuticals3.0434 of 5 stars$5.77+0.4%$11.00+90.8%+141.8%$206.41MN/A-6.7829Analyst RevisionHigh Trading VolumeSCLXScilex2.3831 of 5 stars$26.62-8.9%$455.00+1,609.2%-43.1%$203.18M$44.24M-0.9280CRBUCaribou Biosciences1.8865 of 5 stars$2.30+8.0%$6.67+189.9%+33.5%$198.35M$9.99M-1.29100BIOABioAge Labs0.2746 of 5 stars$5.45+0.6%N/AN/A$194.31MN/A0.00N/ABDTXBlack Diamond Therapeutics3.4996 of 5 stars$3.73+9.7%$11.00+194.9%+6.8%$193.58MN/A16.2290Positive NewsMDWDMediWound1.6309 of 5 stars$17.97+0.4%$32.25+79.5%+7.5%$193.36M$19.86M-6.8180SXTCChina SXT Pharmaceuticals0.4168 of 5 stars$1.62-0.6%N/A-71.8%$189.12M$1.74M0.0090Gap DownCLLSCellectis0.874 of 5 stars$2.84-15.5%$4.00+40.8%+93.9%$186.76M$49.22M-3.46290News CoverageGap UpHigh Trading VolumeFTLFFitLife Brands3.7382 of 5 stars$19.91+0.2%$23.00+15.5%+21.6%$186.70M$64.47M23.7020DERMJourney Medical1.4821 of 5 stars$7.10+0.6%$12.17+71.4%+20.0%$185.75M$56.13M-18.6890News CoveragePositive News Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Competitors Scilex Competitors Caribou Biosciences Competitors BioAge Labs Competitors Black Diamond Therapeutics Competitors MediWound Competitors China SXT Pharmaceuticals Competitors Cellectis Competitors FitLife Brands Competitors Journey Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
